Book Summary
In 1951, Henrietta Lacks, a thirty-one-year-old Black tobacco farmer and mother of five, walked into the colored ward of Johns Hopkins Hospital with vaginal bleeding she had been ignoring for months. The diagnosis was cervical cancer, and the treatment was radium — standard for the time, brutal by any measure. During her treatment, without her knowledge and without her consent, a surgeon shaved a small sample from her tumor and handed it to Dr. George Gey, the hospital’s tissue culturist, who had spent decades trying to do what no one had ever done: keep human cells alive and dividing outside the body indefinitely. Henrietta’s cells did what no human cells had done before. They lived, they divided, and they refused to die — and they have been dividing ever since, in laboratories on every continent, under the name HeLa.
What HeLa made possible is difficult to overstate. Jonas Salk used HeLa cells in developing and testing his polio vaccine. They were used to develop chemotherapy drugs, to advance cloning and gene mapping, to improve in vitro fertilization — and they were among the first human cells ever launched into space. They were also commercialized: within a few years, companies were growing HeLa in bulk and selling vials of it around the world. By one oft-cited estimate, scientists have grown more than 50 million metric tons of HeLa cells — many times the mass of the woman they came from. An entire multibillion-dollar industry traces its lineage to a biopsy taken from a woman whose family could never afford the healthcare her cells helped create.
Henrietta herself died on October 4, 1951, less than a year after her diagnosis, and was buried in an unmarked grave in Virginia. Her family learned about HeLa only decades later, more or less by accident, and spent years confused and frightened — at one point her daughter Deborah believed scientists were keeping her mother alive in a basement somewhere. The Immortal Life of Henrietta Lacks braids three stories together: Henrietta’s short life, the rise of the cell-culture industry, and Skloot’s own decade-long investigation alongside Deborah, as the two women chase down records, interview scientists, and confront the question the book never lets go of: who owns a person’s cells once they leave her body, and who gets paid when they change the world?
Buy The Immortal Life of Henrietta Lacks on Amazon
Who is Rebecca Skloot?
Rebecca Skloot is a science writer who spent more than ten years reporting The Immortal Life of Henrietta Lacks — her first book, published in 2010. Born in 1972 and raised in Portland, Oregon, she first encountered the story of HeLa cells at sixteen, in a biology class, and says she never forgot it — or the fact that the woman behind the cells went unnamed in her textbook. She earned a bachelor’s degree in biology from Colorado State University and an MFA in creative nonfiction from the University of Pittsburgh, and she has been a contributing editor at Popular Science and taught creative writing at the University of Memphis.
The book made Skloot one of the best-known science journalists in America: it spent years on bestseller lists, was adapted into a 2017 HBO film starring Oprah Winfrey as Deborah Lacks and Rose Byrne as Skloot, and it turned its author into an advocate. Skloot founded the Henrietta Lacks Foundation, which gives grants to the Lacks family and to others whose tissues were used in research without consent. She has said the foundation exists because telling the family’s story created an obligation to them — not just a book about them.
Lessons From The Immortal Life of Henrietta Lacks
Consent is the whole game. Henrietta’s cells were taken without her knowledge, in an era when informed consent barely existed as a concept — and the damage compounded for generations. Her children grew up believing their mother might still be alive in a laboratory; researchers drew the family’s blood for decades without clearly explaining why. In business and investing, the lesson is the one compliance departments charge millions to teach: disclose, document, and get clear consent before you take anything that isn’t yours. Trust compounds like returns, and it collapses a lot faster.
Look for the people inside the abstraction. For years, HeLa was a product line — a catalog number, a line item in a lab budget — before anyone in science seriously considered the woman behind it. Markets do the same thing constantly: they turn companies into tickers, workers into headcount, customers into cohorts. The investor who periodically zooms out from the spreadsheet and asks who the humans are — who makes this, who uses this, who gets hurt if this fails — makes better judgments than the one who never looks past the numbers.
Always ask who captures the value. A multibillion-dollar biotechnology industry was built on cells taken from a woman whose family could not afford health insurance. The scientists involved were not villains — Gey gave the cells away freely to colleagues for years — but the economic structure is worth staring at: the raw material was free, the value created was enormous, and the supplier was never paid. When you evaluate a biotech or data company, ask the same question about its inputs. Free raw material is a wonderful business model right up until someone asks where it came from.
Persistence compounds. Gey spent decades failing to culture immortal human cells before Henrietta’s sample arrived. Skloot spent more than ten years earning the Lacks family’s trust and chasing down records. Deborah Lacks spent years demanding answers about her mother. None of them were doing anything that looked productive in any given quarter. The book is, among other things, a tribute to long time horizons — in research, in reporting, and in portfolios, the boring work done consistently for years is what produces the results everyone later calls luck.
Systems repeat their blind spots. The book situates Henrietta’s story in a long history of non-consensual medical research on Black Americans — Johns Hopkins ran segregated wards, and the shadow of the Tuskegee syphilis study hangs over the family’s distrust of doctors. Institutions rarely have malice; they have momentum. They keep doing what they’ve always done until someone forces the question. For an investor, the parallel is direct: every organization, including the ones in your portfolio, has structural blind spots it cannot see from the inside. Audit them from the outside, or pay tuition later.
Buy The Immortal Life of Henrietta Lacks on Amazon
Criticisms of the Book
The science chapters slow the book down. Skloot pauses the narrative repeatedly for primers on cell biology — how cells divide, what a cell line is, how contamination spreads between cultures — and while the explanations are clear, they read like very good textbook chapters inside a great story. Readers who came for the Lacks family will skim; readers who came for the science may wish the primers went deeper. The book sits slightly between two audiences in its middle third, and the pacing sags between the human-story beats.
Skloot also writes herself into the story at considerable length. The book’s third strand is her own decade-long investigation alongside Deborah, and some readers will feel the journalist occupies space that might have belonged to the family. Relatedly, the book was published in 2010 and therefore predates the story’s later chapters: the 2013 agreement between the National Institutes of Health and the Lacks family over access to the HeLa genome, and the family’s 2023 settlement with Thermo Fisher Scientific over the commercialization of the cells. The legal and ethical questions the book raises kept evolving after its last page, and a reader finishing today will want a postscript the book cannot provide.
Who is This Book For?
This is essential reading for anyone who invests in biotechnology or healthcare and has never thought hard about where the industry’s raw materials come from — The Immortal Life of Henrietta Lacks is the human-cost side of the sector’s origin story, and it will permanently change how you read a biotech prospectus. It is equally rewarding for readers of narrative science nonfiction, medical history, and twentieth-century American history: the book is as much about race, class, and consent as it is about cells. If you liked Siddhartha Mukherjee’s The Emperor of All Maladies, this belongs on the same shelf.
Final Thoughts
More than a decade after publication, The Immortal Life of Henrietta Lacks remains the rare book that changed both public understanding and, in small ways, the system it described: it pushed the conversation about consent in research forward, and it helped the Lacks family finally get a seat at the table where decisions about HeLa are made. It is a story about cells that became a story about ownership — of bodies, of data, of the value created from both. In an economy increasingly built on harvesting human inputs at scale, from genomes to browsing histories, the question at the center of this book is only getting more relevant: when something taken from you makes someone else rich, what are you owed?
